Alliance Global analyst Aaron Grey raised the firm’s price target on Organigram (OGI) to C$4 from C$3.60 and keeps a Buy rating on the shares. The company’s fiscal Q4 report beat across metrics on domestic and international sales growth, coupled with margin expansion, the analyst tells investors in a research note. The firm is “encouraged” by Organigram’s momentum and highlights the value of its strategic relationship with BAT.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OGI:
- Midday Fly By: Ford takes $19.5B EV writedown, Apple expanding iPhone lineup
- Morning Movers: Vital Farms dips after cutting FY25 revenue view
- Options Volatility and Implied Earnings Moves Today, December 16, 2025
- Organigram Achieves Record Financial Results and Expands Market Leadership
- Organigram reports Q4 revenue $80.06M, consensus $73.02M